Mental health pharmacists views on shared decision-making for antipsychotics in serious mental illness

Mediha Younas, Eleanor Bradley, Nikki Holmes, Dolly Sud, Ian D. Maidment

Research output: Contribution to journalArticle

Abstract

Background People diagnosed with serious mental illnesses (SMIs) such as schizophrenia and bipolar affective disorder are frequently treated with antipsychotics. National guidance advises the use of shared decision-making (SDM) in antipsychotic prescribing. There is currently little data on the opinions of health professionals on the role of SDM. Objective To explore the views and experiences of UK mental health pharmacists regarding the use of SDM in antipsychotic prescribing in people diagnosed with SMI. Setting The study was conducted by interviewing secondary care mental health pharmacists in the UK to obtain qualitative data. Methods Semi-structured interviews were recorded. An inductive thematic analysis was conducted using the method of constant comparison. Main outcome measure Themes evolving from mental health pharmacists on SDM in relation to antipsychotic prescribing in people with SMI. Results Thirteen mental health pharmacists were interviewed. SDM was perceived to be linked to positive clinical outcomes including adherence, service user satisfaction and improved therapeutic relations. Despite more prescribers and service users supporting SDM, it was not seen as being practised as widely as it could be; this was attributed to a number of barriers, most predominantly issues surrounding service user’s lacking capacity to engage in SDM and time pressures on clinical staff. The need for greater effort to work around the issues, engage service users and adopt a more inter-professional approach was conveyed. Conclusion The mental health pharmacists support SDM for antipsychotic prescribing, believing that it improves outcomes. However, barriers are seen to limit implementation. More research is needed into overcoming the barriers and measuring the benefits of SDM, along with exploring a more inter-professional approach to SDM.

LanguageEnglish
Pages1191–1199
Number of pages9
JournalInternational Journal of Clinical Pharmacy
Volume38
Issue number5
Early online date23 Jul 2016
DOIs
Publication statusPublished - Oct 2016

Fingerprint

Pharmacists
Antipsychotic Agents
Decision Making
Mental Health
Decision making
Health
Professional Role
Secondary Care
Mood Disorders
Bipolar Disorder
Health care
Schizophrenia
Outcome Assessment (Health Care)
Interviews

Bibliographical note

This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were
made.

The online version of this article (doi:10.1007/s11096-016-0352-z) contains supplementary material, which is available to authorized users.

Keywords

  • antipsychotic prescribing
  • mental health pharmacy
  • shared decision making
  • United Kingdom

Cite this

Younas, Mediha ; Bradley, Eleanor ; Holmes, Nikki ; Sud, Dolly ; Maidment, Ian D. / Mental health pharmacists views on shared decision-making for antipsychotics in serious mental illness. In: International Journal of Clinical Pharmacy. 2016 ; Vol. 38, No. 5. pp. 1191–1199.
@article{6665ad8e77f54912b0bb9fff7e8d52a3,
title = "Mental health pharmacists views on shared decision-making for antipsychotics in serious mental illness",
abstract = "Background People diagnosed with serious mental illnesses (SMIs) such as schizophrenia and bipolar affective disorder are frequently treated with antipsychotics. National guidance advises the use of shared decision-making (SDM) in antipsychotic prescribing. There is currently little data on the opinions of health professionals on the role of SDM. Objective To explore the views and experiences of UK mental health pharmacists regarding the use of SDM in antipsychotic prescribing in people diagnosed with SMI. Setting The study was conducted by interviewing secondary care mental health pharmacists in the UK to obtain qualitative data. Methods Semi-structured interviews were recorded. An inductive thematic analysis was conducted using the method of constant comparison. Main outcome measure Themes evolving from mental health pharmacists on SDM in relation to antipsychotic prescribing in people with SMI. Results Thirteen mental health pharmacists were interviewed. SDM was perceived to be linked to positive clinical outcomes including adherence, service user satisfaction and improved therapeutic relations. Despite more prescribers and service users supporting SDM, it was not seen as being practised as widely as it could be; this was attributed to a number of barriers, most predominantly issues surrounding service user’s lacking capacity to engage in SDM and time pressures on clinical staff. The need for greater effort to work around the issues, engage service users and adopt a more inter-professional approach was conveyed. Conclusion The mental health pharmacists support SDM for antipsychotic prescribing, believing that it improves outcomes. However, barriers are seen to limit implementation. More research is needed into overcoming the barriers and measuring the benefits of SDM, along with exploring a more inter-professional approach to SDM.",
keywords = "antipsychotic prescribing, mental health pharmacy, shared decision making, United Kingdom",
author = "Mediha Younas and Eleanor Bradley and Nikki Holmes and Dolly Sud and Maidment, {Ian D.}",
note = "This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The online version of this article (doi:10.1007/s11096-016-0352-z) contains supplementary material, which is available to authorized users.",
year = "2016",
month = "10",
doi = "10.1007/s11096-016-0352-z",
language = "English",
volume = "38",
pages = "1191–1199",
journal = "International Journal of Clinical Pharmacy",
issn = "2210-7703",
publisher = "Springer",
number = "5",

}

Mental health pharmacists views on shared decision-making for antipsychotics in serious mental illness. / Younas, Mediha; Bradley, Eleanor; Holmes, Nikki; Sud, Dolly; Maidment, Ian D.

In: International Journal of Clinical Pharmacy, Vol. 38, No. 5, 10.2016, p. 1191–1199.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Mental health pharmacists views on shared decision-making for antipsychotics in serious mental illness

AU - Younas, Mediha

AU - Bradley, Eleanor

AU - Holmes, Nikki

AU - Sud, Dolly

AU - Maidment, Ian D.

N1 - This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The online version of this article (doi:10.1007/s11096-016-0352-z) contains supplementary material, which is available to authorized users.

PY - 2016/10

Y1 - 2016/10

N2 - Background People diagnosed with serious mental illnesses (SMIs) such as schizophrenia and bipolar affective disorder are frequently treated with antipsychotics. National guidance advises the use of shared decision-making (SDM) in antipsychotic prescribing. There is currently little data on the opinions of health professionals on the role of SDM. Objective To explore the views and experiences of UK mental health pharmacists regarding the use of SDM in antipsychotic prescribing in people diagnosed with SMI. Setting The study was conducted by interviewing secondary care mental health pharmacists in the UK to obtain qualitative data. Methods Semi-structured interviews were recorded. An inductive thematic analysis was conducted using the method of constant comparison. Main outcome measure Themes evolving from mental health pharmacists on SDM in relation to antipsychotic prescribing in people with SMI. Results Thirteen mental health pharmacists were interviewed. SDM was perceived to be linked to positive clinical outcomes including adherence, service user satisfaction and improved therapeutic relations. Despite more prescribers and service users supporting SDM, it was not seen as being practised as widely as it could be; this was attributed to a number of barriers, most predominantly issues surrounding service user’s lacking capacity to engage in SDM and time pressures on clinical staff. The need for greater effort to work around the issues, engage service users and adopt a more inter-professional approach was conveyed. Conclusion The mental health pharmacists support SDM for antipsychotic prescribing, believing that it improves outcomes. However, barriers are seen to limit implementation. More research is needed into overcoming the barriers and measuring the benefits of SDM, along with exploring a more inter-professional approach to SDM.

AB - Background People diagnosed with serious mental illnesses (SMIs) such as schizophrenia and bipolar affective disorder are frequently treated with antipsychotics. National guidance advises the use of shared decision-making (SDM) in antipsychotic prescribing. There is currently little data on the opinions of health professionals on the role of SDM. Objective To explore the views and experiences of UK mental health pharmacists regarding the use of SDM in antipsychotic prescribing in people diagnosed with SMI. Setting The study was conducted by interviewing secondary care mental health pharmacists in the UK to obtain qualitative data. Methods Semi-structured interviews were recorded. An inductive thematic analysis was conducted using the method of constant comparison. Main outcome measure Themes evolving from mental health pharmacists on SDM in relation to antipsychotic prescribing in people with SMI. Results Thirteen mental health pharmacists were interviewed. SDM was perceived to be linked to positive clinical outcomes including adherence, service user satisfaction and improved therapeutic relations. Despite more prescribers and service users supporting SDM, it was not seen as being practised as widely as it could be; this was attributed to a number of barriers, most predominantly issues surrounding service user’s lacking capacity to engage in SDM and time pressures on clinical staff. The need for greater effort to work around the issues, engage service users and adopt a more inter-professional approach was conveyed. Conclusion The mental health pharmacists support SDM for antipsychotic prescribing, believing that it improves outcomes. However, barriers are seen to limit implementation. More research is needed into overcoming the barriers and measuring the benefits of SDM, along with exploring a more inter-professional approach to SDM.

KW - antipsychotic prescribing

KW - mental health pharmacy

KW - shared decision making

KW - United Kingdom

UR - http://www.scopus.com/inward/record.url?scp=84979243129&partnerID=8YFLogxK

U2 - 10.1007/s11096-016-0352-z

DO - 10.1007/s11096-016-0352-z

M3 - Article

VL - 38

SP - 1191

EP - 1199

JO - International Journal of Clinical Pharmacy

T2 - International Journal of Clinical Pharmacy

JF - International Journal of Clinical Pharmacy

SN - 2210-7703

IS - 5

ER -